Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

January 11, 2022

Study Completion Date

March 30, 2022

Conditions
Pain, PostoperativeBunion
Interventions
DRUG

FX301

FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain

DRUG

Normal Saline

Single peripheral nerve injection

Trial Locations (1)

91105

Lotus Clinical Research, Huntington Hospital, Pasadena

Sponsors
All Listed Sponsors
collaborator

Lotus Clinical Research, LLC

OTHER

lead

Pacira Pharmaceuticals, Inc

INDUSTRY

NCT04826328 - Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy | Biotech Hunter | Biotech Hunter